However, recent reports have indicated that IL-17A plays a protective role in T cell-mediated intestinal inflammation [24] and a clinical trial showed that treatment with anti-IL-17A antibodies was ineffective for IBD patients [25]. This evidence concerns the gene IL17A and inflammatory bowel disease.